Unicorn Biotech: Undervalued, Profitable & Cutting Edge Patents...
| |
| EDITOR'S NOTE: Profitable Biotech Enters the Race to Treat Alzheimer's | | | | A Message from i2i Marketing Group Dear Investor,
What would you do if you had a money-printing machine that funded your biggest dreams?
Would you travel the world to far away countries?
Would you open a vineyard and create endless blends of award winning red wine?
What would you do if you had a blank check to explore your passions?
That seems like a pretty sweet gig.
So what if I told you there is a tiny NASDAQ biotech that has one of those machines...
And it's funding all of their R&D efforts in one of the most critical and important sectors to ever exist...
That's right. This tiny $3M biotech has a revenue generating subsidiary that pays for all of their research in helping find a treatment for Alzheimer's disease.
Not only does that de-risk this company from an investor standpoint...
But it could also offer a massive runway to discover a crucial treatment in the race to cure Alzheimer's.
Find out this profitable and potentially critical biotech now in this full report.
This message is a paid advertisement for InMed Pharmaceuticals from i2i Marketing Group. Wealthpire, Inc. has received a fixed fee of $2,500 from InMed Pharmaceuticals for multiple Dedicated Email Sends, and Newsletter Sponsorships. Other than the compensation received for this advertisement sent to subscribers, Wealthpire, Inc. and its principals are not affiliated with either InMed Pharmaceuticals (INM) or i2i Marketing Group. Wealthpire, Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Wealthpire, Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Wealthpire, Inc. to buy or sell any security. Wealthpire, Inc. has not evaluated the accuracy of any claims made in this advertisement. Wealthpire, Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding InMed Pharmaceuticals (INM) on i2i Marketing Group website for additional information about the relationship between i2i Marketing Group and InMed Pharmaceuticals (INM). | | |
|
|
|
| This message is a paid advertisement sent on behalf of i2i Marketing Group, a third-party advertiser of Trading Tips.
From time to time your free Trading Tips newsletter subscription is supplemented by paid sponsorships, like the one above. Please read all disclaimers. Rest assured that your information was not shared with this sponsor. Please note that Trading Tips has not independently reviewed the validity of the claims or statements contained within this sponsorship, and we are not responsible for any errors or omissions.
Never invest in a security or idea featured on our site or in our emails unless you can afford to lose your entire investment. We are not registered investment advisors or brokers/dealers and we do not purport to be. We make no representations, warranties or guarantees as to the accuracy or completeness of the content featured on our site or in our emails. Furthermore, the article authors and contributors featured on this site may own securities mentioned in their articles and not disclose this information. Trading Tips does not endorse any investing or trading products or newsletters advertised in this email or on our web site. Please be sure to read our
Go here to get more information from http://www.TradingTips.com | | | |
|
|
